drugset / Trial / NCT02895815
Efficacy and Safety Study of CNTO 2476 in Participants With Visual Acuity Impairment Associated With Geographic Atrophy (GA) Secondary to Age Related Macular Degeneration (AMD)
RandomizedParallel-groupSingle-blindTreatment
Summary
The purpose of the study is to evaluate the efficacy and safety of CNTO 2476 cells administered into the subretinal space by the suprachoroidal surgical approach and the subretinal access kit (SRAK-02) in participants with visual acuity impairment associated with Geographic Atrophy (GA) secondary to Age Related Macular Degeneration (AMD).
Timeline
- Start
- 2018-04-09
- Primary completion
- 2021-02-20
- Completion
- 2022-08-19
Outcome
Outcome not reported
Stopped (Business): “Company business decision”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CNTO 2476 | Cell therapy | 60000 cells | Other |
| Subject | CNTO 2476 | Cell therapy | 300000 cells | Other |